Clinical profile of idiopathic Parkinson’s disease in patients admitted to Mohamed VI University Hospital center of Marrakech
Objective: Prevalence studies in different parts of the world have shown that Parkinson's disease is a pathology that has a very important impact in older…A Human Factors Study of the DopaFuse® Delivery System
Objective: SynAgile has developed the DopaFuse Delivery System to noninvasively and continuously administer oral LD/CD into the mouths of patients with PD. The System is…An open-label, 1-year extension clinical study in Japan of Opicapone treatment for Parkinson’s disease -Comfort-PD study part 2
Objective: To investigate the safety and efficacy of continuous treatment with 50 mg Opicapone (OPC) for 1 year after treatment with a placebo, 25 mg…Safety and effectiveness of levodopa-carbidopa intestinal gel for advanced Parkinson’s disease : a large single-center study
Objective: To describe adverse events (AEs) associated with levodopa-carbidopa intestinal gel (LCIG) treatment and the main reasons for treatment discontinuation. We also assessed the effectiveness…Prevalence of Parkinson’s disease and parkinsonism in Kyrgyzstan
Objective: Aim of the study is to determine frequency and overall picture of disease characteristics, evaluation and treatment of patients with Parkinson’s disease (PD) and…Can Safinamide Help to Stabilize Dopaminergic Treatment in Parkinson’s Disease?
Objective: After more than two years of clinical experience with safinamide we want to retrospectively review its utility as a levodopa saver in our Parkinson's…Efficacy of carbidopa/levodopa enteral suspension (CLES) in advanced Parkinson’s disease patients previously treated with deep brain stimulation (DBS) – A subgroup analysis from PROviDE study
Objective: To evaluate the effectiveness of carbidopa/levodopa enteral suspension (CLES) on patients with advanced Parkinson’s disease who had previously undergone deep brain stimulation (DBS). Background:…Dynamics of Device-based Treatments for Parkinson´s Disease in Germany from 2010 – 2017
Objective: Analyze the patient profiles and dynamics of utilization of Continuous Subcutaneous Apomorphine Infusion (CSAI), Levodopa-carbidopa Intestinal Gel (LCIG), and Deep Brain Stimulation (DBS) for…The impact of medication and deep brain stimulation on visuo-motor coordination in Parkinson’s disease
Objective: The results presented herein are part of a larger study looking at the impact of medication and deep brain stimulation (DBS) on voluntary and…THOR 201: A Proof-of-Concept Study Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of L-dopa delivered by Impel’s Precision Olfactory Delivery (PODTM) to Parkinson’s Disease Patients in an OFF Episode (in the presence of Dopa Decarboxylase Inhibitor)
Objective: Impel NeuroPharma has developed the patient-friendly, self or caregiver actuatedPrecision Olfactory Delivery (IMPEL PODTM) device to achieve consistent upper nasal cavity drug delivery, rapid…
- « Previous Page
- 1
- …
- 42
- 43
- 44
- 45
- 46
- …
- 70
- Next Page »